A retrospective historical analysis of @entity1 under 18 years of age with the histopathological diagnosis of @entity6196 ( @entity6196 ) is presented. The survey embraced two different groups of @entity1 . Group 1 was defined as those @entity1 treated from 1972 to 1984 with surgical resection plus neuraxis radiotherapy alone. Group 2 was made up of @entity1 treated from 1990 to 1996 with the same approach but with the addition of adjuvant chemotherapy: @entity900 (day 1) and etoposide (days 1-3) every 3 weeks for 6 months. Group 1 embraced 42 @entity1 with an age range of 1-16 years (mean 6 years, SD 4.4 years). In group 2 there were 34 @entity1 , their ages ranging from 1 to 18 years (mean 7.2, SD 4.6 years). The prevalence of stages T2M0 and T3M0 was similar in both groups, but in group 1 there were 4 @entity1 (9.5%) whose spinal fluid was positive for @entity5 cells (M1), while in group 2 there were 7 @entity1 (20.5%) with positive spinal fluid. There was an unequivocal initial response to treatment in 86% of these @entity1 in group 1 and in 79% in group 2. The event-free survival (EFS) was 30% at 252 months in group 1, while for group 2 the EFS was 67.6% at 63 months (P 0.002). Mortality from @entity5 activity was noted in 26 @entity1 (70%) in group 1, while in group 2 mortality attributable to @entity5 progression was documented in 11 @entity1 (32%). We conclude that the use of adjuvant chemotherapy in these @entity1 improves survival without any significant morbidity.

Is the ancillary chemotherapy approach of any value in the treatment of XXXX with surgery and radiotherapy?

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity6196 :: ('MESH:D018242', 'Disease') :: ['PNET', 'infratentorial primitive neuroectodermal tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor']
@entity6196 :: (MESH:D018242,Disease) :: ['infratentorial primitive neuroectodermal tumors']
